Related Experiment Video

Updated: Sep 27, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Smad4 transcriptional pathways and angiogenesis

Irmgard Schwarte-Waldhoff1, Wolff Schmiegel

  • 1Ruhr-Universität Bochum, Medizinische Universitätsklinik, Knappschaftskrankenhaus, Germany. Irmgard.Schwarte-Waldhoff@ruhr-uni-bochum.de

International Journal of Gastrointestinal Cancer
|March 8, 2003
PubMed

Insights

Restoring the Smad4 tumor suppressor gene suppressed gastrointestinal cancer growth in vivo. Smad4

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Smad4 (DPC4) is a tumor suppressor gene frequently inactivated in gastrointestinal cancers.
  • Smad4 is a key intracellular mediator of TGF-beta signaling, which normally inhibits epithelial cell growth.
  • Tumor cells often exhibit resistance to TGF-beta, and Smad4 loss is presumed to contribute to this resistance.

Purpose of the Study:

  • To investigate the tumor suppressor functions of Smad4 by restoring its expression in deficient cancer cells.
  • To elucidate the mechanisms by which Smad4 suppresses tumor growth beyond TGF-beta signaling.

Main Methods:

  • Stable re-expression of Smad4 in human colon and pancreatic cancer cell lines.
  • In vivo tumor growth assessment in nude mice.
  • In vitro cell growth assays.
  • Analysis of gene expression related to angiogenesis (VEGF, TSP-1).

Main Results:

  • Smad4 re-expression potently suppressed tumor growth in vivo.
  • Smad4 restoration did not significantly suppress tumor cell growth in vitro or restore TGF-beta responsiveness.
  • Smad4 influenced angiogenesis by decreasing vascular endothelial growth factor (VEGF) and increasing thrombospondin-1 (TSP-1) expression.

Conclusions:

  • Smad4's tumor suppressor function extends beyond TGF-beta pathway mediation.
  • Loss of Smad4 and acquisition of TGF-beta resistance may be independent events in tumorigenesis.
  • Smad4 regulates tumor growth through the control of angiogenesis, representing a novel tumor suppression mechanism.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...